June 25-26, 2020

3rd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress - Virtual Event (Time Zone - ET)

45+
Speakers
200+
Attendees
4
Networking Hours
5+
Sessions

Due to growing concerns about COVID-19, the 3rd Annual MarketsandMarkets Next Gen IO Congress is going fully virtual this year. We are disappointed that we are not able to come together in person in June for this event, but we are so thrilled to see you on an online platform. We are working together to create a virtual conference that will be beneficial and engaging for speakers, attendees and sponsors/exhibitors.

See the Post Show report of our 2nd Annual here

Please write to [email protected] for questions regarding speaking, attending and sponsoring. We will keep you posted with the event flow soon. Keep checking our website.

WHAT TO EXPECT
Key Highlights
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Monoclonal Antibody & Cellular Therapy
  • Neoantigens in personalized Cancer Immunotherapy
  • Biomarkers and Cancer Vaccines
  • Developments in CAR-T Cellular Therapy
  • Oncolytic Viral Therapy & Personalized Medicine
  • Engineering Cellular Therapies Beyond Traditional Tumor Antigens
  • Combination Therapies in I/O
Why attend Virtual?
  • Exclusive Virtual event to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive Q&A sessions with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
CONFERENCE AGENDA
Monoclonal Antibody & Cellular Therapy

Registration

10:40 - 10:50

Opening remark by Chairperson

10:50 - 11:00

Immunotherapy in 2020: Beyond checkpoint inhibition and CAR T cell

11:00 - 11:25 Geert Mudde, CSO and Managing Director, Founder, OncoQR ML GmbH, S-TARget therapeutics

Panel Discussion: The promises of CAR-T cell therapy in 2020 and beyond

11:25 - 12:00

Targeting AXL to leverage checkpoint immunotherapy: Updated results of the BGBC008 phase II study of bemcentinib and pembrolizumab in recurrent NSCLC

12:00 - 12:30 Hani Gabra , Chief Medical Officer , BerGenBio

Mechanisms of Resistance and Response to anti-CD19 CAR T cell Therapy in LC

12:30 - 12:55 John Rossi, Director, Translational Sciences , Kite Pharma

Targeting Bispecific Antibodies and Developing Systems Disease Models in I/O

12:55 - 13:25 John M. Burke, President, CEO, and Co-founder  , Applied BioMath

REGN4018, a Mucin 16 bispecific T cell engaging antibody for the treatment of ovarian cancer

13:25 - 13:50 Alison Crawford, Sr. Staff Scientist, Regeneron Pharmaceuticals, Inc.
Antibodies & CAR-T Cellular Therapy

Laboratory Considerations for Immuno-Oncology Clinical Trials - Q2 Solutions

13:50 - 14:05

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

14:05 - 14:30 Eric Halioua, President & CEO, PDC*line Pharma

Deciphering the function of B cells in human cancer

14:30 - 14:55 Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh

Closing remark by chairman

14:55 - 15:00

Networking│One-to-One Networking Meetings

15:00 - 15:30

End of Day 1

15:30 - 15:30
Advancing Precision Medicine: Emerging Therapeutic and Technological Approaches

Registration

10:40 - 10:50

Opening remark by Chairperson

10:50 - 11:00

Are there still unmet needs in ICI therapy?

11:00 - 11:25 Stefan Gluck, Vice President, Global Head Franchise Oncology, Regeneron

Cannabinoids as companion treatments for cancer

11:25 - 11:50 Philip Arlen, Chief Scientific Officer, Senior Vice President, Diverse Biotech

Solution Provider Presentation - Biocytogen

11:50 - 12:20

Solution Provider Presentation - Proteome Sciences

12:20 - 12:50

FDA Accelerated Approval Pathways for Cell and Gene Therapy 

12:50 - 13:20

A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer 

13:20 - 13:45 Indu Venugopal , Research Scientist, SRI International
Cancer Vaccines & Biomarkers

Solution Provider Presentation - PromoCell GmbH

13:45 - 14:15

First-in-class biotherapeutics, designed to “heat up” cold tumor microenvironment for combination therapy with PD(L)1 inhibitors

14:15 - 14:40 Christie Zhang , Project Team Leader, Elstar Therapeutics

Oncolytic Viruses: NOTCHing up the game

14:40 - 15:05 Balveen Kaur, Professor, The University of Texas Health Science Center

Closing remark by chairman

15:05 - 15:10

Networking│One-to-One Networking Meetings

15:10 - 15:40

End of Day 1

15:40 - 15:40
Therapeutics antibodies & TCR-based Cellular Therapy

Registrations

10:40 - 10:55

Opening remark by Chairperson

10:55 - 11:00

PD-1 Antibodies are Transforming Cancer Care

11:00 - 11:25 Roy Baynes , Senior Vice President and Head, Global Clinical Development, Chief Medical Officer, Merck Sharp & Dohme

Development of a Next Generation Anti-Cancer Immunotherapy: A Humanized anti-BTN3A Antibody that Activates Gamma-Delta (Vg9-Vd2) T Cells

11:25 - 11:50 Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics

Novel serum-free and xeno-free T cell medium for improved T cell therapy manufacturing

11:50 - 12:20

Solution Provider Presentation - PhenoSwitch Bioscience Inc.

12:20 - 12:50

Completing the immune cycle by targeting novel macrophage checkpoints

12:50 - 13:15 Tatiana Novobrantseva, Co-founder and Chief Scientific Officer, Verseau Therapeutics

Solution Provider Presentation - PHC Corporation

13:15 - 13:45

Unleashing the Power of SQZ’d Cells to Engineer a New Generation of Cancer Vaccines

13:45 - 14:10 Katherine Seidl, Vice President Immunology Research and Development, SQZ Biotechnologies

Closing remarks from Chairman

14:10 - 14:15

Networking│One-to-One Networking Meetings

14:15 - 14:45

End of Conference

15:00 - 15:00

Registrations

10:40 - 10:55

Opening remark by Chairperson

10:55 - 11:00

Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy 

11:00 - 11:25 Nuzhat Pathan, Director, Early Development, Translational and Immuno-Oncology, Pfizer

Cancer Immunotherapy: A Targeted, Personalized and Off-the-Shelf Approach

11:25 - 11:50 William Williams, President, CEO, Briacell Therapeutics Corporation

Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models

11:50 - 12:20 Sebastien Tabruyn, CSO, TransCure bioServices SAS, France

Unleashing the power of NGS to unlock the secrets of immuno-oncology 

12:20 - 12:50 Raed Samara Ph.D , Associate Director, Global Product Management, NGS , QIAGEN

Preventing drug resistance to targeted therapeutics in ER+HER2- Breast Cancer

12:50 - 13:15 Nathaniel Wang, Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson

Preclinical modeling of immune responses to Cancer: improving translatability of bench-side discoveries to clinical outcomes

13:15 - 13:40 Mithun Khattar, Immuno-Oncology Lead, Takeda Oncology

It’s time to look beyond Checkpoint Blockade

13:40 - 14:05 Shailesh Dudhgaonkar , Deputy Research Director , Biocon Bristol Myers Squibb R&D Center (BBRC)

Closing remarks from Chairman

14:05 - 14:10

Networking│One-to-One Networking Meetings

14:10 - 15:00

End of Conference

15:00 - 15:00
CONFERENCE SPEAKERS
Speakers
Shailendra Singh (Shelly)

Shailendra Singh (Shelly)

Board Member
MarketsandMarkets

Shailendra Singh (Shelly)

Board Member
MarketsandMarkets
Roy Baynes

Roy Baynes

Senior Vice President
Merck

Roy Baynes

Senior Vice President
Merck
Mithun Khattar

Mithun Khattar

Immuno-Oncology Lead
Takeda Oncology

Mithun Khattar

Immuno-Oncology Lead
Takeda Oncology
Stefan Gluck

Stefan Gluck

Vice President, Global Head Franchise Oncology
Regeneron

Stefan Gluck

Vice President, Global Head Franchise Oncology
Regeneron
Nuzhat Pathan

Nuzhat Pathan

Director, Early Development, Translational and Immuno-Oncology
Pfizer

Nuzhat Pathan

Director, Early Development, Translational and Immuno-Oncology
Pfizer
Philip Arlen

Philip Arlen

Chief Scientific Officer, Senior Vice President
Diverse Biotech

Philip Arlen

Chief Scientific Officer, Senior Vice President
Diverse Biotech
Nathaniel Wang

Nathaniel Wang

Oncology Vaccines Project Leader
Janssen, Pharmaceutical Companies of Johnson and Johnson

Nathaniel Wang

Oncology Vaccines Project Leader
Janssen, Pharmaceutical Companies of Johnson and Johnson
Shailesh Maingi

Shailesh Maingi

Founder and CEO
Kineticos Life Sciences

Shailesh Maingi

Founder and CEO
Kineticos Life Sciences
SPONSORS
Gold
example-image

BIOCYTOGEN

example-image

Applied BioMath

example-image

QIAGEN

Silver
example-image

PhenoSwitch Bioscience

Sponsors & Exhibitors
example-image

PromoCell

example-image

TransCure bioServices

example-image

BerGenBio

example-image

Imaging Endpoints

example-image

Q2 Solutions

example-image

CellGenix

example-image

Thermo Fisher Scientific

example-image

PHC Group

example-image

PHC Group

example-image

PHC Group

example-image

Proteome Sciences

example-image

Eppendorf

example-image

Cook Regentec

example-image

BioIVT

example-image

NeoGenomics

PAST EVENT GALLERY
  • Networking-Room
  • Networking-Event
  • Networking-Exhibition-Audience
  • Networking-Exhibition
  • Discussion-Conference-Audience
  • Conference-Speaker
  • Conference-Audience-Discussion
  • Conference-Room-Audience
  • Conference-Room
  • Conference-Audience
  • High Potent Medicines Conference - Networking area
  • High Potent Medicines Conference - Exhibition Area - Booths